Pharmaxis Receives Negative Recommendation from PADAC

31st Jan 13

Release Date: 31/01/2013 12:00am

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has received a negative recommendation from a Committee advising the US Food and Drug Administration (FDA) on the use of Bronchitol® for cystic fibrosis patients in the United States.

 

Read full media release - pdf

Categories: News and Media